Trump announces trade deal with EU following months of negotiations
WALTHAM, Mass. - OptimizeRx Corp. (NASDAQ:OPRX), a healthcare technology company with a market capitalization of $240 million and impressive year-to-date returns of 167%, has appointed its Chief Executive Officer Steve Silvestro to its Board of Directors, effective June 20, 2025, according to a company statement.
Silvestro, who joined OptimizeRx in 2019, has served as CEO since March 2025, after holding the interim CEO position from January 2025. He previously worked as the company’s President from October 2023 to January 2025 and Chief Commercial Officer from April 2019.
Lynn Vos, Chairperson of OptimizeRx’s Board, said, "The initiatives he and the leadership team have executed have significantly strengthened OptimizeRx’s position with customers and laid a solid foundation for sustained long-term shareholder value creation."
Prior to joining OptimizeRx, Silvestro served as Vice President and General Manager at CCH Tagetik, a Wolters Kluwer company, from January 2018 to April 2019. He also worked as Chief Commercial Officer at Prognos Health, Inc. from April 2017 to January 2018, and held various positions at Decision Resources Group from 2007 to 2017.
Silvestro stated that the company would focus on "delivering exceptional customer experiences, deepening our value proposition with pharmaceutical partners, accelerating our shift toward a recurring revenue model, and progressing toward Rule of 40 performance."
OptimizeRx describes itself as a healthcare technology company that helps life sciences companies connect with healthcare professionals and patients through its platform that combines AI-driven tools for audience targeting and engagement.
The information in this article is based on a press release issued by OptimizeRx.
In other recent news, OptimizeRX Corp reported its Q1 2025 earnings, revealing a revenue of $21.9 million, which surpassed the projected $19.1 million. Despite a slight miss in earnings per share (EPS), the company showed an 11% year-over-year revenue growth. The transition to a subscription-based model is progressing, with strong revenue visibility for the year. OptimizeRX has also increased its full-year revenue guidance to between $101 million and $106 million, with adjusted EBITDA expected to range from $13 million to $15 million.
Analysts have responded positively to these developments, with Stifel raising its price target for OptimizeRX to $16 and maintaining a Buy rating, citing optimism about the company’s strategic focus and financial performance. Similarly, JMP Securities increased its price target to $14, highlighting revised revenue projections and improved adjusted EBITDA estimates for 2025 and 2026. The company’s management expressed confidence in its strategic initiatives and financial outlook, with over 80% revenue visibility reported for the year. These updates reflect a positive sentiment from market analysts regarding OptimizeRX’s growth potential and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.